Nopol-Based Quinoline Derivatives as Antiplasmodial Agents

Area of Science:

• Medicinal Chemistry
• Parasitology
• Drug Discovery

Background:

• Malaria causes significant morbidity and mortality, particularly in Sub-Saharan Africa and South Asia.
• Antimalarial drug resistance is a persistent global health challenge, necessitating the development of new therapeutics.
• Existing antimalarials require complementary strategies to effectively combat malaria, especially in tropical regions.

Purpose of the Study:

• To investigate the antimalarial activity of novel nopol-based quinoline derivatives against Plasmodium falciparum.
• To evaluate the efficacy of these compounds against both chloroquine-sensitive and chloroquine-resistant strains of the malaria parasite.
• To identify potential lead compounds for future antimalarial drug development.

Main Methods:

• Synthesis of nopol-based quinoline derivatives, including nopyl-quinolin-8-yl amides and nopyl-quinolin-4-yl analogs.
• In vitro testing of synthesized compounds against asexual blood stages of Plasmodium falciparum strains (Pf3D7, PfK1, PfNF54).
• Structure-activity relationship analysis to determine the impact of chemical modifications on antimalarial activity.

Main Results:

• Nopyl-quinolin-8-yl amides (compounds 2-4) exhibited moderate activity against the chloroquine-sensitive Pf3D7 strain but were inactive against resistant strains (PfK1, PfNF54).
• Nopyl-quinolin-4-yl amides and acetates showed generally lower activity across all tested strains.
• A specific compound, amide 8 with a C7 chloro substituent, displayed sub-micromolar EC50 against the PfK1 strain, but significantly reduced activity against other strains.

Conclusions:

• Nopyl-quinolin-8-yl amides share an antimalarial profile similar to 8-aminoquinolines like primaquine, targeting the asexual blood stage.
• The selective activity of compound 8 against resistant strains warrants further investigation.
• Future research should focus on evaluating promising derivatives against gametocyte or liver stages of Plasmodium falciparum and Plasmodium vivax.